What You Should Know:
- C2i Genomics, a cancer intelligence company launches its C2inform minimal residual disease (MRD) test across Europe, after obtaining CE-IVD marking in the EU, UK and Switzerland. The company also announced the completion of several clinical trials across the globe, including leading cancer centers in Europe, U.S. and Singapore.
- The new clinical data will be presented at the 2022 American Association for Cancer Research (AACR) annual meeting in New Orleans,
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
MLB Taps Cue Health to Expand League-Wide COVID-19 Testing Program for 2022 Season
What You Should Know:
- Cue Health Inc. (“Cue”), a healthcare technology company, and Major League Baseball (MLB) today announced a national partnership that expands Cue’s support of the league-wide COVID-19 testing program.
- Serving As MLB’s trusted at-home testing solution, Cue will provide Major League Clubs as well as the MLB league office with its integrated care platform, featuring both the portable and reusable Cue Health Monitoring
Read More
Labcorp & Medidata to Co-Develop Digital Biomarkers & Expand Decentralized Clinical Trials
What You Should Know:
- Medidata, a Dassault Systèmes company, today announced that Labcorp, a leading global life sciences company, has selected Medidata's technology platform to extend their 14-year partnership, the foundation of their initiative to co-develop digital biomarkers and expand the use and functionality of decentralized clinical trials. Labcorp Drug Development has developed its offerings on Medidata technologies, starting with Rave EDC
Read More
4C Medical Technologies Nabs $35M, Appoints New President and CEO
What You Should Know:
- 4C Medical Technologies, a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease raises $35.4M in Series C funding was led by MicroPort CardioFlow Medtech Corporation (HKEX:2160).
- The Company's AltaValve® would be the first MR treatment with atrial-only fixation that is designed to minimize known issues associated with current TMVR technologies,
Read More
BillionToOne Raises $125M to Expand Genetic Testing Platform
What You Should Know:
- BillionToOne, a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all raises $125M in Series C funding co-led by Adams Street Partners and existing investor Hummingbird Ventures with significant participation from Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Civilization Ventures, Fifty Years VC, Pacific 8 Ventures, Time BioVentures, and Libertus Capital, among others.
- This
Read More
VivoSense Raises $25M for Wearable Sensor Biomarkers to Advance Clinical Trials
What You Should Know:
- VivoSense, an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data raises $25 Million in Series A funding.
- The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments. VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital
Read More
LetsGetChecked Acquires Veritas Genetics To Leverage Whole Genome Sequencing
What You Should Know:
- Healthcare solutions company LetsGetChecked, today announced the acquisition of genomics pioneer Veritas Genetics and Veritas Intercontinental.
- Through these acquisitions, LetsGetChecked will leverage the power of whole-genome sequencing to launch a full lifecycle of personalized healthcare, delivering the most comprehensive health testing and care solution on the market.
LetsGetChecked, a leading healthcare solutions company acquires Veritas Genetics Inc.
Read More
ConcertAI Raises $150M at $1.9 Billion Valuation for RWD Platform
What You Should Know:
- ConcertAI, LLC (ConcertAI), the leader in enterprise AI and real-world data (RWD) solutions for life sciences and healthcare, announced the close of its $150M in Series C led by Sixth Street at a $1.9B valuation.
- From its startup just five years ago, ConcertAI has emerged as one of the fastest-growing companies providing high-value software-as-a-service (SaaS) and data solutions to life sciences and biopharma companies, leading healthcare providers, contract
Read More
CPQ: Optimizing MedTech Operations and Sales to Accelerate Cash Flow
The lead-to-cash process in most B-to-B organizations––particularly those operating in the medical device industry––is often complex and lengthy. This is even more apparent when operations, sales and customer success teams operate in manual and siloed environments.
In this all-too-common scenario, not only does it slow cash flow velocity, it also leaves the organization vulnerable to inconsistencies, inaccuracies and more errors every time a handoff occurs between
Read More
Tempus Launches Pathology-Driven AI Platform
What You Should Know:
- Tempus, a provider of artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide.
- With access to over 50 petabytes of de-identified multimodal data, Tempus is developing AI models with the aim to identify patients who would
Read More
